The patient perspective on vaccine uptake in adults with psoriasis and eczema.

"Declarations Conflict of interestMaryam Asgari receives royalty payments from UptoDate. Joel Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), and Sanofi and Pfizer Inc., receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, OrthoDermatologics, and Pfizer Inc., and he has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Joel Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. Arash Mostaghimi has received consulting fees from Pfizer, hims and hers, Digital Diagnostics, Concert, Lilly, Abbvie, Bioniz, Acom, Equillium, Boehringer Ingelheim; equity from hims, Fig 1, ACOM; licensing/royalties from Pfizer, Concert; and research funding from Incyte, Lilly, Aclaris, Concert. Megan Noe has received research grants from Boehringer Ingelheim and Bristol Myers Squibb for projects unrelated to this manuscript. John Barbieri is an Associate Editor for JAMA Dermatology. Joel Gelfand is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology, and is the Chief Medical Editor for Healio Psoriatic Disease for which he received honoraria. Arash Mostaghimi is an associate editor for JAMA Dermatology. Megan Noe is senior editor for the Journal of Psoriasis and Psoriatic Arthritis. Marjorie Archila, Lourdes M. Perez-Chada, Nathaniel Goldman, Christina G. Lopez, and Alice J. Tan have nothing to disclose. Ethical approvalThis study was performed in line with the principles of the Declaration of Helsinki and was approved by The Mass General Brigham Institutional Review Board. Consent to participateVerbal informed consent was obtained from each prior to participation. Conflict of interest Maryam Asgari receives royalty payments from UptoDate. Joel Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), and Sanofi and Pfizer Inc., receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, OrthoDermatologics, and Pfizer Inc., and he has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Joel Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. Arash Mostaghimi has received consulting fees from Pfizer, hims and hers, Digital Diagnostics, Concert, Lilly, Abbvie, Bioniz, Acom, Equillium, Boehringer Ingelheim; equity from hims, Fig 1, ACOM; licensing/royalties from Pfizer, Concert; and research funding from Incyte, Lilly, Aclaris, Concert. Megan Noe has received research grants from Boehringer Ingelheim and Bristol Myers Squibb for projects unrelated to this manuscript. John Barbieri is an Associate Editor for JAMA Dermatology. Joel Gelfand is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology, and is the Chief Medical Editor for Healio Psoriatic Disease for which he received honoraria. Arash Mostaghimi is an associate editor for JAMA Dermatology. Megan Noe is senior editor for the Journal of Psoriasis and Psoriatic Arthritis. Marjorie Archila, Lourdes M. Perez-Chada, Nathaniel Goldman, Christina G. Lopez, and Alice J. Tan have nothing to disclose."

"Funding This study was funded by a K23 Career Development Award (K23-AR073932) from the National Institute of Arthritis, Musculoskeletal and Skin Diseases (MHN). Dr. Scherer also received funding from a K01 Mentored Research Scientist Development Award from the National Institute on Aging (NIA- 1K01AG065440), and Dr. Asgari received funding from a Midcareer Investigator Award in Patient-Oriented Research (5K24AR069760) from National Institute of Arthritis, Musculoskeletal and Skin Diseases."